-
Posted by
Two Blokes Jun 17 -
Filed in
Stock
-
8 views
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has unveiled new research demonstrating how its Parsortix liquid biopsy system, combined with next-generation sequencing, can uncover genetic differences missed by standard blood-based tests in lung cancer patients. Presented today at the European Association for Cancer Research congress in Lisbon, the study highlights the benefits of analysing DNA from both circulating tumour cells (CTCs) and cell-free tumour DNA (ctDNA) extracted from the same blood sample.
